Cancer Clinical Trials Office

    The Cancer Clinical Trials Office within Mayo Clinic Comprehensive Cancer Center supports both researchers and people with cancer by providing centralized management, oversight and reporting functions related to activating and conducting cancer clinical trials.

    The Cancer Clinical Trials Office also works with Community Outreach and Engagement to ensure that the people who participate in our research are truly representative of the communities we serve.

    By offering a variety of services that facilitate and strengthen research, the Cancer Clinical Trials Office provides a comprehensive infrastructure that ensures high-quality, efficient cancer clinical trials.


    Protocol development services

    A dedicated team of protocol development specialists in the Cancer Clinical Trials Office develops, coordinates and activates studies written by Mayo Clinic researchers, studies within cooperative groups, and studies sponsored by industry.

    These specialists have experience and expertise in protocol development supported by awards related to federal, foundation and industry studies. They support activities involving budget compilation and submission to the Institutional Review Board at Mayo Clinic. They also offer consultation and guidance to researchers on sponsor engagement throughout the life cycle of a protocol.

    Services include:


    Regulatory, compliance and quality assurance services

    A team of regulatory affairs specialists, regulatory affairs coordinators and compliance coordinators in the Cancer Clinical Trials Office provides regulatory guidance about policies and procedures to investigators, study teams and internal review committees. The regulatory team may also review protocols to ensure accurate and complete regulatory information.

    The Cancer Clinical Trials Office ensures high-quality standards for data collection and clinical trials management. The office has quality-management resources to maintain patient safety and high-quality clinical trials operations while proactively providing real-time feedback to staff, improving audit outcomes and furthering staff collaboration.

    Regulatory services include:

    • Submitting regulatory documents and reporting adverse events to Mayo Clinic committees and external agencies.
    • Submitting and maintaining U.S. Food and Drug Administration (FDA) investigational new drug and device applications.
    • Supporting an electronic regulatory binder system used by investigators and study teams.

    Compliance services include:

    • Planning and implementing compliance activities.
    • Interpreting and applying regulatory and policy requirements.
    • Helping develop and plan education programs for Mayo Clinic and external collaborators.

    Quality assurance services include:

    • An internal monitoring and auditing program for investigator-initiated trials. These services include:
      • Reviewing and comparing data entered into a data capture system against information in patient source documents to ensure protocol compliance and data integrity.
      • Reviewing regulatory documentation to ensure that requirements are met for the Institutional Review Board, good clinical practices and the FDA.
      • Conducting meetings or exit interviews with principal investigators and study teams to discuss findings.
      • Writing reports for monitoring or auditing.
    • First- and third-subject and regulatory reviews designed to help identify educational or procedural gaps, or both, across studies and study teams.
    • Assisting with electronic data capture system testing.
    • Performing data reviews, data queries and data cleaning of the electronic data capture system.
    • Other quality reviews to ensure proper reporting and submission of complete documentation about adverse events and deviations to the Institutional Review Board.

    Study coordination services

    Clinical research coordinators support activities related to identifying and recruiting participants for studies, enrolling them into studies, and managing them according to study protocols. The coordinators are responsible for timely, accurate collection and reporting of study data, including adverse events.

    Services include:

    • Identifying, screening and recruiting eligible study participants.
    • Verifying eligibility criteria.
    • Obtaining informed consent from study participants.
    • Ensuring studies are conducted according to their protocols.
    • Collecting and maintaining accurate study data in a timely manner.
    • Providing ongoing support and communication with study participants.

    Operational support services

    General operational activities within the Cancer Clinical Trials Office include:

    • Improving and automating processes.
    • Continuing education.
    • Developing policies, standard operating procedures and best practices.

    Selecting and prioritizing clinical trials

    The Cancer Clinical Trials Office works with Mayo Clinic Comprehensive Cancer Center's research programs and disease groups to activate clinical research studies that meet the needs of everyone in our catchment areas, prioritizing their most important cancer challenges.

    The Cancer Center's 15 disease groups partner with Community Outreach and Engagement representatives to select, prioritize and develop clinical trials that address the exact needs of the communities we serve. These groups are led by Sarah A. McLaughlin, M.D., deputy director for disease groups.

    The 15 disease groups are:

    • Breast cancer.
    • Central nervous system cancer/neuro-oncology.
    • Experimental and novel therapeutics:
      • Early-phase therapeutics novel agents.
      • Cellular therapies and gene and viral therapies.
      • Radiopharmaceuticals.
    • Gastrointestinal cancer:
      • Colorectal.
      • Gastroesophageal.
    • Genitourinary cancer.
    • Gynecologic cancer.
    • Head and neck cancer.
    • Hepato-pancreatico-biliary cancer.
    • Thoracic malignancies.
    • Lymphoid malignancies:
      • Chronic lymphocytic leukemia.
      • Lymphoma.
    • Myeloid malignancies and blood/marrow transplant:
      • Acute leukemia and myeloid neoplasms.
      • Bone marrow transplant.
    • Myeloma.
    • Pediatric oncology:
      • Adolescent and young adult.
      • Pediatrics.
    • Population science and community interventions:
      • Behavioral, community-based and care-delivery research.
      • Precision risk assessment and interception.
      • Symptom control and survivorship.
    • Rare cancers:
      • Endocrine malignancies.
      • Melanoma and skin cancers.
      • Sarcoma and bone and soft tissue cancers.

    Enterprise leadership

    Grzegorz S. Nowakowski, M.D.
    Deputy Director, Clinical Research

    Angela H. Fritsche, M.P.A.
    Operations Administrator, Clinical Research

    Katie M. Van Abel, M.D.
    Chair, Protocol Review and Monitoring System

    Aaron S. Mansfield, M.D.
    Chair, Data, Safety and Monitoring

    Jian L. Campian, M.D., Ph.D.
    Associate Medical Director, Protocol Development

    Geoffrey B. Johnson, M.D., Ph.D.
    Associate Medical Director, Enterprise Radiology

    Daniel J. Ma, M.D.
    Associate Medical Director, Enterprise Radiation Oncology

    Rory L. Smoot, M.D.
    Associate Medical Director, Enterprise Surgery


    Site-based leaders

    Javier L. Munoz, M.D., M.B.A.
    Associate Medical Director, Arizona

    Mohamed A. Kharfan Dabaja, M.D., M.B.A.
    Associate Medical Director, Florida

    Thor R. Halfdanarson, M.D.
    Associate Medical Director, Rochester, Minnesota


    Contact us

    For more information about the Cancer Clinical Trials Office and clinical research at Mayo Clinic Comprehensive Cancer Center, contact:

    Grzegorz S. Nowakowski, M.D.
    Deputy Director, Clinical Research
    Email: nowakowski.grzegorz@mayo.edu

    Angela H. Fritsche, M.P.A.
    Operations Administrator, Clinical Research
    Email: fritsche.angela@mayo.edu


    3X your impact!

    Your gift can go 3X as far to shape the future of healthcare.